Kidney Injury Causes Accumulation Of Renal Sodium That Modulates Renal Lymphatic Dynamics

Abstract

Lymphatic vessels are highly responsive to changes in the interstitial environment. Previously, we showed renal lymphatics express the Na-K-2Cl cotransporter. Since interstitial sodium retention is a hallmark of proteinuric injury, we examined whether renal sodium affects NKCC1 expression and the dynamic pumping function of renal lymphatic vessels. Puromycin aminonucleoside (PAN)-injected rats served as a model of proteinuric kidney injury. Sodium 23Na/1H-MRI was used to measure renal sodium and water content in live animals. Renal lymph, which reflects the interstitial composition, was collected, and the sodium was analyzed. The contractile dynamics of isolated renal lymphatic vessels were studied in a perfusion chamber. Cultured lymphatic endothelial cells (LECs) were used to assess direct sodium effects on NKCC1. MRI showed elevation in renal sodium and water in PAN. In addition, renal lymph contained higher sodium, although the plasma sodium showed no difference between PAN and controls. High sodium decreased contractility of renal collecting lymphatic vessels. In LECs, high sodium reduced phosphorylated NKCC1 and SPAK, an upstream activating kinase of NKCC1, and eNOS, a downstream effector of lymphatic contractility. The NKCC1 inhibitor furosemide showed a weaker effect on ejection fraction in isolated renal lymphatics of PAN vs controls. High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide. We propose that this lymphatic vessel dysfunction is a novel mechanism of impaired interstitial clearance and edema in proteinuric kidney disease.

Keywords

kidney; lymphatics; sodium; NKCC1 transporter.

Click here to know the effect of Cistanche and buy the Cistanche extract

Introduction

Sodium retention is a well-documented consequence of many pathophysiological conditions, especially kidney disease, which is clinically recognized as an accumulation of edema [1]. Previous studies found sodium retention in skin and muscle is connected to blood pressure regulation involving lymphatic remodeling [2–4]. Recent research indicates that sodium, along with water, accumulates systemically, including in the lung, liver, muscles, and myocardium [5,6]. While kidneys have a central role in regulating sodium homeostasis, few studies have quantified kidney sodium or water content, including in edema-forming conditions. Such studies have been primarily limited by a lack of methodology for sodium quantification in vivo. Recent developments in noninvasive sodium imaging by 23Na-MRI provide an attractive tool for quantifying kidney sodium content in vivo. Moreover, although kidney disease is regularly accompanied by lymphatic vessel hyperplasia [7–14], whether disease-induced lymphangiogenesis is accompanied by disrupted renal lymphatic vessel dynamics is unknown. Lymphatics are important because unlike blood flow, which relies on the heart as a central pump, lymph flow is propelled by forces in the surrounding tissues and by active rhythmic contractions intrinsic to the lymphatic vessels themselves. These intrinsic mechanisms constitute a major force in lymphatic flow and are exquisitely sensitive to the microenvironment, for example, hydraulic pressure, shear stress, local tissue temperature, and sodium [15]. A recent study provides evidence that lymphangiogenesis accompanying arthritis in TNF-transgenic mice reflects intrinsic dysfunction in popliteal lymphatic vessels that are linked to NOSdependent as well as independent impairment in lymphatic vessel dynamics that may drive arthritic damage of the joint [16]. Whether intrarenal sodium modulates renal lymphatic contractions has not been reported.

Lymphatic vessel contractility is driven by action potentials that trigger Ca++ influx generated by ion channels and transporters. We recently showed the Na-K-2Cl cotransporter NKCC1, but not NKCC2 is expressed in renal lymphatic vessels [17]. While NKCC2 is best known for its actions on tubular epithelial cells responsible for the maintenance of sodium homeostasis, NKCC1 is increasingly recognized as a modulator of various unanticipated biological functions, including regulation of vascular tone [18]. Indeed, inhibition of NKCC1 and its activating kinases has become a novel antihypertensive strategy involving direct (non-diuretic) vascular dilation. However, in contrast to blood vessels, little is known about NKCC transporter expression, activity, or function in the lymphatic vascular network and how the microenvironment or disease alters these parameters. This is particularly relevant since the first line of intervention in the treatment of edema and underlying interstitial clearance impairment is NKCC inhibition by furosemide.

Here we assessed whether kidney injury affects renal sodium content, how a high sodium environment alters the pumping dynamics of renal collecting lymphatic vessels, and the role of NKCC1 in this response.

Cistanche tubulosa

Discussion

A high-sodium environment is a critical modulator of lymphatic vessels. Although kidneys are central in Na+ homeostasis, little is understood about Na+ effects on renal lymphatics. The current studies provide new insights into the regulation of the renal lymphatic network by showing (1) proteinuric kidney injury increases renal Na+ by 23Na/1H MRI and direct sampling of renal lymphatic fluid shows elevated Na+ concentration while plasma Na+ is unchanged (2) high Na+ and furosemide inhibition of NKCC1 decrease lymphatic vessel contraction amplitude and ejection fraction in isolated renal lymphatic vessels, (3) a high Na+ environment decreases phosphorated-NKCC1, phosphorylated SPAK, an upstream kinase, and phosphorylated eNOS, a downstream vasoactive factor, and (4) a high Na+ environment together with renal injury contribute to a blunted lymphatic response in PAN-injured kidneys.

Noninvasive imaging by 23Na/1H MRI showed that proteinuric kidney injury leads to the accumulation of sodium and water in the in vivo kidneys. This new observation reflects advances in multi-nuclear imaging technology that exploit endogenous 23Na, the second most abundant magnetic nuclei in living systems [25]. Imaging methods are advantageous for longitudinal measurement of tissue sodium before and after the intervention, localization of tissue sodium in renal sub-compartments, and comparison of multi-modal data, strategies explored in this study. The findings of this study demonstrate 23Na-MRI quantification of renal sodium as a potential biomarker of renal disease involving lymphatic clearance dysfunction. Imaging results, supported by data, suggest that lymph exiting proteinuric kidneys has significantly higher sodium concertation than the renal lymph of normal, uninjured control rats. Sodium levels in the blood of these proteinuric animals were not different from normal rats. To date, there are only sparse data on the composition of renal lymph, especially in disease settings, although more than 50 years ago, two studies describing partial occlusion of the inferior vena cava model of right heart failure found the increased renal lymphatic flow and sodium content [26,27]. More recently, sodium accumulation in the skin of salt-sensitive hypertensive rats was shown to be accompanied by increased sodium concentration in lymph collected from dermal lymphatic vessels, while no change in the circulating level of sodium was observed [4]. These findings reinforce the concept that lymph reflects the composition of the interstitial compartment of the draining organ. Our data make the original observation that kidney injury leads to renal sodium accumulation, although the study did not localize sodium to any specific interstitial compartment [1]. Sodium accumulation in the interstitium has been linked to the modulation of lymphatic vessels, especially lymphangiogenesis. This has been most extensively studied in the skin of hypertensive animals and humans and involves transcription factor tonicity-responsive enhancer protein (TonEBP)-induced macrophage secretion of vascular endothelial growth factor-C (VEGF-C) [4]. Although kidney injury causes renal lymphangiogenesis and modulates sodium reabsorption and excretion, there have been no studies on the possible effects of accumulating interstitial sodium on renal lymphatic function. We now show that direct exposure of renal lymphatic vessels to a high-sodium environment increases the frequency of contraction in the renal collecting lymphatic vessels and reduces the contraction amplitude, and, to a lesser extent, the ejection fraction. These results complement findings that a high-salt diet, or DOCA treatment that increases sodium in skin and muscle, increases contraction frequency while reducing contraction amplitude [19]. These observations are timely, since strategies to improve interstitial clearance currently target lymphatic network growth, although the efficacy appears to be context-dependent. Thus, activation of the VEGF-C–VEGFR-3 pathway to promote lymphangiogenesis can reduce kidney fibrosis and lessen cystic kidney disease in mice and rats [9]. Also, kidney-specific overexpression of VEGF-D before injury increased lymphatic density and amplified recovery from ischemia-reperfusion damage [28]. In contrast, inhibition of VEGFR-3 reduces kidney lymphangiogenesis, glomerulosclerosis, and tubulointerstitial fibrosis in a mouse model of diabetic kidney disease as well as fibrosis following UUO and ischemia-reperfusion [10]. Our data suggest that high interstitial sodium blunts lymphatic dynamics and may be a critical factor contributing to the efficacy of the therapeutic intervention.

Cistanche supplement

Currently, the first-line therapy to reduce sodium overload in a variety of diseases, including kidney disease, is the inhibition of NKCC cotransporter with furosemide. Immunohistochemical staining demonstrated NKCC1 in endothelial cells of renal collecting lymphatic vessels, and quantitation of mRNA showed increased gene expression in PAN vessels vs collecting vessels of uninjured kidneys. However, a high-sodium environment significantly reduced the phosphorylation of NKCC1 in LECs. Moreover, a high-sodium environment also reduced the phosphorylation of SPAK, the upstream kinase of NKCC1, suggesting sodium dampens lymphatic contractility. Previous studies showed high salt downregulated phosphorylation and ubiquitination of WNK [29], which reduced the expression of SPAK and NKCC1. Zeniya et al. showed suppressed phosphorylation of NKCC1 in mouse aortae fed a high-salt diet and stimulated phosphorylation of NKCC1 in mice on a low-salt diet [22]. Similar to our results with direct sodium exposure, a high-salt diet caused a divergent effect on the gene and protein expression of upstream kinases. Together, these data fit well with evidence that, aside from maintaining extracellular fluid volume, sodium acts as a signaling molecule.

NKCC1 activity can contribute to both vasoconstriction and vasodilation. Vasoconstrictors such as norepinephrine, endothelin, and angiotensin II directly activate NKCC1 activity in vascular smooth muscle cells, causing constriction, while NO and sodium nitroprusside inhibit NKCC1, resulting in vasodilation [30,31]. High-sodium environments reduce phosphorylated eNOS, which would predict reduced vasodilation but increased contractility. Indeed, inhibiting NO signaling with L-NAME decreased end diastolic and end systolic vessel diameter, the amplitude of contraction, calculated ejection fraction, and increased contraction frequency in renal lymphatic vessels. Interestingly, previous studies confirm that a high-salt diet and/or direct exposure of lymphatic vessels to a high-sodium environment increases contraction frequency in skin and muscle lymphatics and inguinal lymphatic vessels of mice and rats [19,32,33].

Our data clearly show that a high-sodium environment directly blunts lymphatic dynamics. Since lymphatic vessels are exquisitely sensitive to environmental stimuli, other molecules within the renal interstitial compartment including vasoactive substances, for example, angiotensin II, may also play a role in lymphatic dynamic functions. However, comparison with vessels from PAN-injured kidneys exposed to a high-sodium environment revealed that renal injury is an additive contributor to lymphatic dysfunction. Thus, injured vessels exposed to high sodium showed a diminution in their ability to respond to a pathological shift in their environment. This constellation of findings predicts impaired drainage of the renal interstitium in settings where a high interstitial sodium environment may prevail, such as in congestive heart failure, cirrhosis, and acute and chronic kidney disease. Moreover, these are the very conditions that show relative resistance to interventions that promote sodium excretion by inhibition of NKCC1. Notably, the ejection fraction in PAN-injured vessels is less affected by increasing concentrations of furosemide. Currently, therapeutic resistance to these agents centers on impaired delivery of the therapeutic to the relevant tubular segment. However, based on our data, we propose that dysfunction of renal lymphatic vessels is related to electrolyte abnormalities in the microenvironment of the kidney.

Cistanche capsules

Conclusions

Based on our data, we propose that the dysfunction of renal lymphatic vessels is related to electrolyte abnormalities. Furthermore, although lymphangiogenesis has been firmly established to accompany these conditions, our data suggest that sodium-induced lymphatic dysfunction compounds the problem of impaired fluid clearance in the setting of kidney injury. Sodium accumulation suppresses the pumping function of renal lymphatic vessels by inhibiting the SPAK-NKCC1 cascade. These results imply that the lymphatic system should be viewed as a potential target in diseases characterized by sodium accumulation, such as various renal diseases or heart failure.

References

1. Ellison, D.H.; Welling, P. Insights into Salt Handling and Blood Pressure. N. Engl. J. Med. 2021, 385, 1981–1993. [CrossRef] [PubMed]

2. Mullins, L.; Ivy, J.; Ward, M.; Tenstad, O.; Wiig, H.; Kitada, K.; Manning, J.; Rakova, N.; Muller, D.; Mullins, J. Abnormal Neonatal Sodium Handling in Skin Precedes Hypertension in the SAME Rat. Pflugers Arch. 2021, 473, 897–910. [CrossRef] [PubMed]

3. Rabelink, T.J.; Rotmans, J.I. Salt Is Getting Under Our Skin. Nephrol. Dial. Transplant. 2009, 24, 3282–3283. [CrossRef] [PubMed]

4. Wiig, H.; Schröder, A.; Neuhofer, W.; Jantsch, J.; Kopp, C.; Karlsen, T.V.; Boschmann, M.; Goss, J.; Bry, M.; Rakova, N.; et al. Immune Cells Control Skin Lymphatic Electrolyte Homeostasis and Blood Pressure. J. Clin. Investig. 2013, 123, 2803–2815. [CrossRef] [PubMed]

5. Matthay, M.A.; Zemans, R.L.; Zimmerman, G.A.; Arabi, Y.M.; Beitler, J.R.; Mercat, A.; Herridge, M.; Randolph, A.G.; Calfee, C.S. Acute Respiratory Distress Syndrome. Nat. Rev. Dis. Primers 2019, 5, 18. [CrossRef]

6. Rossitto, G.; Mary, S.; Chen, J.Y.; Boder, P.; Chew, K.S.; Neves, K.B.; Alves, R.L.; Montezano, A.C.; Welsh, P.; Petrie, M.C.; et al. Tissue Sodium Excess Is Not Hypertonic and Reflects Extracellular Volume Expansion. Nat. Commun. 2020, 11, 4222. [CrossRef]

7. Abouelkheir, G.R.; Upchurch, B.D.; Rutkowski, J.M. Lymphangiogenesis: Fuel, Smoke, or Extinguisher of Inflammation’s Fire? Exp. Biol. Med. (Maywood) 2017, 242, 884–895. [CrossRef]

8. Donnan, M.D.; Kenig-Kozlovsky, Y.; Quaggin, S.E. The Lymphatics in Kidney Health and Disease. Nat. Rev. Nephrol. 2021, 17, 655–675. [CrossRef]

9. Hasegawa, S.; Nakano, T.; Torisu, K.; Tsuchimoto, A.; Eriguchi, M.; Haruyama, N.; Masutani, K.; Tsuruya, K.; Kitazono, T. Vascular Endothelial Growth Factor-C Ameliorates Renal Interstitial Fibrosis through Lymphangiogenesis in Mouse Unilateral Ureteral Obstruction. Lab. Investig. 2017, 97, 1439–1452. [CrossRef]

10. Hwang, S.D.; Song, J.H.; Kim, Y.; Lim, J.H.; Kim, M.Y.; Kim, E.N.; Hong, Y.A.; Chung, S.; Choi, B.S.; Kim, Y.S.; et al. Inhibition of Lymphatic Proliferation by the Selective VEGFR-3 Inhibitor SAR131675 Ameliorates Diabetic Nephropathy in db/db Mice. Cell Death Dis. 2019, 10, 219. [CrossRef]

11. Kerjaschki, D.; Huttary, N.; Raab, I.; Regele, H.; Bojarski-Nagy, K.; Bartel, G.; Kröber, S.M.; Greinix, H.; Rosenmaier, A.; Karlhofer, F.; et al. Lymphatic Endothelial Progenitor Cells Contribute to De Novo Lymphangiogenesis in Human Renal Transplants. Nat. Med. 2006, 12, 230–234. [CrossRef] [PubMed]

12. Pei, G.; Yao, Y.; Yang, Q.; Wang, M.; Wang, Y.; Wu, J.; Wang, P.; Li, Y.; Zhu, F.; Yang, J.; et al. Lymphangiogenesis in Kidney and Lymph Node Mediates Renal Inflammation and Fibrosis. Sci. Adv. 2019, 5, eaaw5075. [CrossRef] [PubMed]

13. Yazdani, S.; Poosti, F.; Kramer, A.B.; Mirkovi´c, K.; Kwakernaak, A.J.; Hovingh, M.; Slagman, M.C.; Sjollema, K.A.; de Borst, M.H.; Navis, G.; et al. Proteinuria Triggers Renal Lymphangiogenesis Before the Development of Interstitial Fibrosis. PLoS ONE 2012, 7, e50209. [CrossRef] [PubMed]

14. Zarjou, A.; Black, L.M.; Bolisetty, S.; Traylor, A.M.; Bowhay, S.A.; Zhang, M.Z.; Harris, R.C.; Agarwal, A. Dynamic Signature of Lymphangiogenesis During Acute Kidney Injury and Chronic Kidney Disease. Lab. Investig. 2019, 99, 1376–1388. [CrossRef]

15. Solari, E.; Marcozzi, C.; Negrini, D.; Moriondo, A. Lymphatic Vessels and Their Surroundings: How Local Physical Factors Affect Lymph Flow. Biology 2020, 9, 463. [CrossRef] [PubMed]

16. Scallan, J.P.; Bouta, J.P.; Rahimi, H.; Kenney, H.M.; Ritchlin, C.T.; Davis, C.T.; Schwarz, E.M. Ex vivo Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis. Front. Physiol 2021, 12, 745096. [CrossRef]

17. Shelton, E.L.; Yang, H.C.; Zhong, J.; Salzman, M.M.; Kon, V. Renal Lymphatic Vessel Dynamics. Am. J. Physiol. Renal. Physiol. 2020, 319, F1027–F1036. [CrossRef]

18. Dormans, T.P.; Pickkers, P.; Russel, F.G.; Smits, P. Vascular Effects of Loop Diuretics. Cardiovasc. Res. 1996, 32, 988–997. [CrossRef]

19. Karlsen, T.V.; Nikpey, E.; Han, J.; Reikvam, T.; Rakova, N.; Castorena-Gonzalez, J.A.; Davis, M.J.; Titze, J.M.; Tenstad, O.; Wiig, H. High-Salt Diet Causes Expansion of the Lymphatic Network and Increased Lymph Flow in Skin and Muscle of Rats. Arter. Thromb. Vasc. Biol. 2018, 38, 2054–2064. [CrossRef]

20. Balasubramanian, D.; Baranwal, G.; Clark, M.C.; Goodlett, B.L.; Mitchell, B.M.; Rutkowski, J.M. Kidney-specific lymphangiogenesis increases sodium excretion and lowers blood pressure in mice. J. Hypertens. 2020, 38, 874–885. [CrossRef]

21. Delpire, E.; Gagnon, K.B. Na(+)-K(+)-2cl(−) Cotransporter (Nkcc) Physiological Function in Nonpolarized Cells and Transporting Epithelia. Compr. Physiol. 2018, 8, 871–901. [CrossRef]

22. Zeniya, M.; Sohara, E.; Kita, S.; Iwamoto, T.; Susa, K.; Mori, T.; Oi, K.; Chiga, M.; Takahashi, D.; Yang, S.S.; et al. Dietary Salt Intake Regulates WNK3-SPAK-NKCC1 Phosphorylation Cascade in Mouse Aorta through Angiotensin II. Hypertension 2013, 62, 872–878. [CrossRef] [PubMed]

23. Baldwin, S.N.; Sandow, S.L.; Mondéjar-Parreño, G.; Stott, J.B.; Greenwood, I.A. K(V)7 Channel Expression and Function within Rat Mesenteric Endothelial Cells. Front. Physiol. 2020, 11, 598779. [CrossRef] [PubMed]

24. Li, Y.; Wu, X.; Mao, Y.; Liu, C.; Wu, Y.; Tang, J.; Zhao, K.; Li, P. Nitric Oxide Alleviated High Salt-Induced Cardiomyocyte Apoptosis and Autophagy Independent of Blood Pressure in Rats. Front. Cell Dev. Biol. 2021, 9, 646575. [CrossRef] [PubMed]

25. Madelin, G.; Lee, J.S.; Regatte, R.R.; Jerschow, A. Sodium MRI: Methods and Applications. Prog. Nucl. Magn. Reson. Spectrosc. 2014, 79, 14–47. [CrossRef] [PubMed]

26. Katz, Y.J.; Cockett, A.; Moor, R.S. Elevation of Inferior Vena Cava Pressure and Thoracic Lymph and Urine Flow. Circ. Res. 1959, 7, 118–122. [CrossRef]

27. Lebrie, S.J.; Mayerson, H.S. Influence of Elevated Venous Pressure on Flow and Composition of Renal Lymph. Am. J. Physiol. 1960, 198, 1037–1040. [CrossRef]

28. Baranwal, G.; Creed, H.A.; Black, L.M.; Auger, A.; Quach, A.M.; Vegiraju, R.; Eckenrode, H.E.; Agarwal, A.; Rutkowski, J.M. Expanded Renal Lymphatics Improve Recovery Following Kidney Injury. Physiol. Rep. 2021, 9, e15094. [CrossRef]

29. Zhao, X.; Lai, G.; Tu, J.; Liu, S.; Zhao, Y. Crosstalk between Phosphorylation and Ubiquitination Is Involved in High Salt-Induced WNK4 Expression. Exp. Ther. Med. 2021, 21, 133. [CrossRef]

30. Akar, F.; Jiang, G.; Paul, R.J.; O’Neill, W.C. Contractile Regulation of the Na(+)-K(+)-2cl(−) Cotransporter in Vascular Smooth Muscle. Am. J. Physiol. Cell Physiol. 2001, 281, C579–C584. [CrossRef]

31. Akar, F.; Skinner, E.; Klein, J.D.; Jena, M.; Paul, R.J.; O’Neill, W.C. Vasoconstrictors and Nitrovasodilators Reciprocally Regulate the Na+-K+-2cl- Cotransporter in Rat Aorta. Am. J. Physiol. 1999, 276, C1383–C1390. [CrossRef] [PubMed]

32. Kwon, S.; Agollah, G.D.; Sevick-Muraca, E.M.; Chan, W. Altered Lymphatic Function and Architecture in Salt-Induced Hypertension Assessed by Near-Infrared Fluorescence Imaging. J. Biomed. Opt. 2012, 17, 080504. [CrossRef]

33. Mizuno, R.; Isshiki, M.; Ono, N.; Nishimoto, M.; Fujita, T. A High-Salt Diet Differentially Modulates Mechanical Activity of Afferent and Efferent Collecting Lymphatics in Murine Iliac Lymph Nodes. Lymphat. Res. Biol. 2015, 13, 85–92. [CrossRef] [PubMed]

34. Hueper, K.; Gutberlet, M.; Brasen, J.H.; Jang, M.S.; Thorenz, A.; Chen, R.; Hertel, B.; Barrmeyer, A.; Schmidbauer, M.; Meier, M.; et al. Multiparametric Functional Mri: Non-Invasive Imaging of Inflammation and Edema Formation after Kidney Transplantation in Mice. PLoS ONE 2016, 11, e0162705. [CrossRef] [PubMed]

35. Schley, G.; Jordan, J.; Ellmann, S.; Rosen, S.; Eckardt, K.U.; Uder, M.; Willam, C.; Bauerle, T. Multiparametric Magnetic Resonance Imaging of Experimental Chronic Kidney Disease: A Quantitative Correlation Study with Histology. PLoS ONE 2018, 13, e0200259. [CrossRef]

36. Scallan, J.P.; Zawieja, S.D.; Castorena-Gonzalez, J.A.; Davis, M.J. Lymphatic Pumping: Mechanics, Mechanisms, and Malfunction. J. Physiol. 2016, 594, 5749–5768. [CrossRef]

Jing Liu 1,2, Elaine L. Shelton 2,3, Rachelle Crescenzi 4, Daniel C. Colvin 4, Annet Kirabo 5, Jianyong Zhong 2,6, Eric J. Delpire 7, Hai-Chun Yang 2,6 and Valentina Kon 2

1 Department of Nephrology, Tongji University School of Medicine, Shanghai 200070, China; liujing961226@163.com

2 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA

3 Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; elaine.l.shelton@vumc.org

4 Department of Radiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; rachelle.crescenzi@vumc.org (R.C.); daniel.colvin@vumc.org (D.C.C.)

5 Department of Medicine, Division of Clinal Pharmacology and Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; annet.kirabo@vanderbilt.edu (A.K.); jianyong.zhong@vumc.org (J.Z.)

6 Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; eric.delpire@vanderbilt.edu

7 Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA